Clinical Study - Ref7P12
European Journal of Drug Metabolism and PharmacoKinetics, 1992, Vol. 17, No.1, pp.39-44
Siliphos® versus Silybin
Comparative bioavailability of IbD 1016 (Siliphos®), a new flavanolignan complex, in rats
P. Morazzoni1, M.J. Magistretti1, C. GIACHETTI2 and G. ZANOLO2
1 Inverni della Beffa Rasearch and Development Laboratories, Milan, Italy
2 "Antoine Marxer" Institute for Biomedical Research, Ivrea, Italy
The results of this study indicate a superior bioavailabilty of silybin administered orally as IbD 1016 (Siliphos®). This was due mainly to an impressive increase in gastrointestinal absorbtion.
It also clearly confirmed that pure silybin has a very low bioavailability; indeed, administered by oral route it does not result in detectable plasma levels of either unmodified or total silybin.